Benchmark analyst Doug Becker initiates coverage on NOV (NYSE:NOV) with a Hold rating.
Benchmark Initiates Coverage On NOV with Hold Rating
Benchmark analyst Doug Becker initiates coverage on NOV (NYSE:NOV) with a Hold rating.
Related Posts
Analyst Ratings for Sarepta Therapeutics
Over the past 3 months, 24 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts…
Starbucks Ailed By Slower Top-line, Stiff Competition: Analyst Cuts Forecast
Guggenheim analyst reiterated a Neutral rating on Starbucks, lowering the price target to $100 from $101. Shares are not particularly expensive at 23x C'24 EPS for mid-teens EPS growth, the analyst adds.
The Real Brokerage Says Company Increased Its Presence In Chicago And Surrounding States With Addition Of Qamar Group
The company announced that Qamar Group has joined the company. Led by CEO Rafay Qamar and COO Jana Pierce, the team brings 36 agents who serve Chicago and its suburbs, Michigan and Wisconsin.
Ranked among the